Payment overview · 2025
General Payments
$366.64
18 reported records · 6 companies
Healthcare provider profile · identity verified
Frank Aran-Serrano, MD
Allopathic & Osteopathic Physicians|Family Medicine · ORLANDO, FL · NPI 1700031911
Verified facts
What the public records show
CMS Open Payments records show Frank Aran-Serrano, MD received $366.64 in general payments during 2025 across 18 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $89.77 | 24.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $72.33 | 19.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $68.28 | 18.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.57 | 14.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.20 | 14.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.49 | 8.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $366.64 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $89.77 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $72.33 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $68.28 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.66 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.83 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.83 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.83 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.49 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.49 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 740 | 274 |
| Amlodipine Besylate | Amlodipine Besylate | 504 | 173 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 410 | 164 |
| Lisinopril | Lisinopril | 401 | 146 |
| Metformin Hcl | Metformin Hcl | 389 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 130 |
| Losartan Potassium | Losartan Potassium | 355 | 128 |
| Gabapentin | Gabapentin | 317 | 114 |
| Omeprazole | Omeprazole | 284 | 101 |
| Fluticasone Propionate | Fluticasone Propionate | 234 | 111 |
| Simvastatin | Simvastatin | 231 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 73 |
| Carvedilol | Carvedilol | 172 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 64 |
| Celecoxib | Celecoxib | 135 | 64 |
| Jardiance | Empagliflozin | 131 | 51 |
| Finasteride | Finasteride | 128 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 57 |
| Furosemide | Furosemide | 121 | 47 |
| Glipizide Er | Glipizide | 113 | 41 |
| Trazodone Hcl | Trazodone Hcl | 111 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 42 |
| Eliquis | Apixaban | 103 | 35 |
| Januvia | Sitagliptin Phosphate | 101 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 99 | 36 |
| Baclofen | Baclofen | 98 | 46 |
| Montelukast Sodium | Montelukast Sodium | 98 | 38 |
| Alendronate Sodium | Alendronate Sodium | 87 | 27 |
| Famotidine | Famotidine | 87 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 36 |
| Meloxicam | Meloxicam | 85 | 25 |
| Ozempic | Semaglutide | 80 | 29 |
| Glimepiride | Glimepiride | 79 | 32 |
| Methylprednisolone | Methylprednisolone | 79 | 69 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 75 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 26 |
| Allopurinol | Allopurinol | 71 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 21 |
| Mirtazapine | Mirtazapine | 61 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 20 |
| Ezetimibe | Ezetimibe | 57 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 26 |
| Glipizide | Glipizide | 55 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 19 |
| Metformin Hcl Er | Metformin Hcl | 53 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 27 |
| Atenolol | Atenolol | 49 | 17 |
| Donepezil Hcl | Donepezil Hcl | 49 | 21 |
| Enalapril Maleate | Enalapril Maleate | 49 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 15 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 16 |
| Buspirone Hcl | Buspirone Hcl | 46 | 23 |
| Spironolactone | Spironolactone | 44 | 18 |
| Lactulose | Lactulose | 43 | 22 |
| Nifedipine Er | Nifedipine | 43 | 16 |
| Clonidine Hcl | Clonidine Hcl | 41 | 17 |
| Sertraline Hcl | Sertraline Hcl | 40 | 18 |
| Lovastatin | Lovastatin | 39 | 13 |
| Potassium Chloride | Potassium Chloride | 38 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | 12 |
| Clonazepam | Clonazepam | 36 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 17 |
| Novolog Flexpen | Insulin Aspart | 33 | 11 |
| Lorazepam | Lorazepam | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 15 |
| Valsartan | Valsartan | 32 | 12 |
| Entresto | Sacubitril/Valsartan | 30 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 11 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Tramadol Hcl | Tramadol Hcl | 26 | 14 |
| Acyclovir | Acyclovir | 25 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Prednisone | Prednisone | 25 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 12 |
| Ibuprofen | Ibuprofen | 24 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | 11 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Ondansetron Odt | Ondansetron | 19 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Benzonatate | Benzonatate | 15 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $366.64 · 18 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, JARDIANCE, Kerendia, OTEZLA, PREVNAR 20, REPATHA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error